Flow cytometric enrichment for respiratory epithelial cells in sputum

Petra S. Kraemer1, Carissa A. Sanchez2,1, Gary E. Goodman1,3, James R. Jett4, Peter S. Rabinovitch5,1, Brian J. Reid6,7,2,1
1Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington
2Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington
3Swedish Hospital Medical Center Tumor Institute, Seattle, Washington
4Department of Pulmonary Medicine and Medical Oncology, Mayo Clinic, Rochester, Minnesota
5Department of Pathology, University of Washington, Seattle, Washington
6Department of Genome Sciences, University of Washington, Seattle, Washington
7Department of Medicine, University of Washington, Seattle, Washington

Tóm tắt

AbstractBackground

Induced sputum, in contrast to bronchoscopic biopsies and lavages, is an easily obtained source of biological specimens. However, obtaining abnormal exfoliated cells for detailed molecular studies is limited because respiratory epithelial cells comprise only about 1% of sputum cell populations.

Methods

We developed a multiparameter flow sorting strategy to purify epithelial cells from nonepithelial sputum cells, using anti‐cytokeratin antibody AE1/AE3 to recognize human epithelial cells and DAPI to stain DNA. We excluded cells with a high degree of side‐scatter, which were composed predominantly of squamous cells and contaminating macrophages. The remaining cytokeratin‐positive respiratory epithelial cells were then sorted based on anti‐cytokeratin (PE) vs DNA (DAPI) parameters.

Results

In this proof of principle study, the AE1AE3 cytokeratin/DNA flow sorting strategy enriched rare diploid respiratory epithelial cells from an average of 1.1% of cells in unsorted induced sputum samples to average purities of 42%. Thus, AE1AE3 flow‐sorting results in a 38‐fold enrichment of these cells.

Conclusions

We report a multiparameter flow cytometric assay to detect and enrich rare respiratory epithelial cells from induced sputum samples to average purities of 42%. With further development, this methodology may be useful as part of a molecular screening approach of populations at high risk for lung cancer. © 2004 Wiley‐Liss, Inc.

Từ khóa


Tài liệu tham khảo

10.3322/canjclin.51.1.15

10.1002/ijc.1440

10.1002/(SICI)1097-0215(19990924)83:1<18::AID-IJC5>3.0.CO;2-M

10.3322/canjclin.52.1.23

Ries LAG, 2003, SEER cancer statistics review, 1975–2000

10.1001/archinte.162.17.1985

Cancer Statistics Branch NCI, 1988, SEER extent of disease, 1

10.1038/nrc1041

10.1378/chest.86.1.44

10.1002/1097-0142(19910215)67:4 <1155::AID-CNCR2820671509>3.0.CO;2-0

10.1097/00043764-198608000-00038

10.1093/jnci/92.16.1308

10.1002/1097-0142(20001201)89:11 <2356::AID-CNCR8>3.0.CO;2-Z

10.1002/(SICI)1097-4644(1996)25 <177::AID-JCB25>3.0.CO;2-K

10.1200/JCO.1998.16.9.3061

10.1002/ijc.2910630611

Miozzo M, 1996, Microsatellite alterations in bronchial and sputum specimens of lung cancer patients, Cancer Res, 56, 2285

10.1200/JCO.2000.18.18.3221

10.1073/pnas.95.20.11891

Palmisano WA, 2000, Predicting lung cancer by detecting aberrant promoter methylation in sputum, Cancer Res, 60, 5954

Mao L, 1994, Detection of oncogene mutations in sputum precedes diagnosis of lung cancer, Cancer Res, 54, 1634

10.1200/JCO.1988.6.11.1685

Qiao YL, 1997, A case‐cohort study of an early biomarker of lung cancer in a screening cohort of Yunnan tin miners in China, Cancer Epidemiol Biomarkers Prev, 6, 893

Gilliland FD, 2002, Glutathione S‐transferase P1 and NADPH quinone oxidoreductase polymorphisms are associated with aberrant promoter methylation of P16(INK4a) and O(6)‐methylguanine‐DNA methyltransferase in sputum, Cancer Res, 62, 2248

Belinsky SA, 2002, Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers, Cancer Res, 62, 2370

10.1073/pnas.91.21.9871

Tockman MS, 1997, Prospective detection of preclinical lung cancer: results from two studies of heterogeneous nuclear ribonucleoprotein A2/B1 overexpression, Clin Cancer Res, 3, 2237

Kips JC, 1998, Methods of examining induced sputum: do differences matter?, Eur Respir J, 11, 529, 10.1183/09031936.98.11030529

10.1183/09031936.96.09122448

Peleman RA, 1995, Sputum analysis in chronic obstructive pulmonary disease (COPD): comparison of two methods, Am J Respir Crit Care Med, 151, A486

10.1164/ajrccm.162.3.9908057

10.1164/ajrccm.161.2.9903097

10.1183/09031936.98.12030595

10.1378/chest.123.4.1054

10.1073/pnas.93.14.7081

10.1038/8816

Blount PL, 1994, 17p allelic losses in diploid cells of patients with Barrett's esophagus who develop aneuploidy, Cancer Res, 54, 2292

Barrett MT, 1996, Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus, Oncogene, 13, 1867

10.1002/(SICI)1097-0320(19960701)24:3<260::AID-CYTO9>3.0.CO;2-L

Wong DJ, 2001, p16 INK4a lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium, Cancer Res, 61, 8284

10.1111/j.1572-0241.2001.04236.x

10.1093/jnci/91.24.2087

10.1016/0016-5085(93)90017-7

Tockman MS, 1995, Safe separation of sputum cells from mucoid glycoprotein, Acta Cytol, 39, 1128

10.1006/clim.2000.4911

Blount PL, 1991, 17p allelic deletions and p53 protein overexpression in Barrett's adenocarcinoma, Cancer Res, 51, 5482

10.1016/0016-5085(92)90759-R

10.1073/pnas.90.8.3221

Burmer GC, 1989, Analysis of c‐Ki‐ras mutations in human colon carcinoma by cell sorting, polymerase chain reaction, and DNA sequencing, Cancer Res, 49, 2141

10.1016/0016-5085(90)91024-Z

10.3727/095535491820873254

10.1016/0016-5085(92)91184-6

Prevo LJ, 1999, p53‐mutant clones and field effects in Barrett's esophagus, Cancer Res, 59, 4784

Barrett MT, 1999, Molecular pathology of early cancer, 179

10.1016/0016-5085(87)90306-4

10.1016/0016-5085(92)90758-Q

10.1111/j.1572-0241.2000.02196.x

10.1111/j.1572-0241.2001.03844.x

10.1111/j.1572-0241.2001.05261.x

10.1016/S0002-9440(10)64351-9

10.1101/gr.10.8.1126

10.1093/jn/132.8.2388S

10.1007/BF03326425

Wong DJ, 1997, p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas, Cancer Res, 57, 2619

10.1093/jnci/93.14.1054